Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Dec. 27 to 31, 2021. This […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Dec. 27 to 31, 2021. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
Adverse Events Rare After BNT162b2 Vaccine in 5- to 11-Year-Olds
THURSDAY, Dec. 30, 2021 (HealthDay News) — Children aged 5 to 11 years rarely report adverse events after Pfizer-BioNTech COVID-19 vaccination, and 97.6 percent of the adverse events are not serious, according to research published in the Dec. 31 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
BNT162b2 Vaccine Effectiveness 92 Percent for Teens Ages 12 to 17
THURSDAY, Dec. 30, 2021 (HealthDay News) — For adolescents ages 12 to 17 years, the effectiveness of full vaccination with two doses of the Pfizer-BioNTech vaccine is 92 percent against severe acute respiratory syndrome coronavirus 2, according to research published in the Dec. 31 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Severe Illness, Viral Coinfection Common in Children With COVID-19 Hospitalization
THURSDAY, Dec. 30, 2021 (HealthDay News) — Many pediatric patients with COVID-19-related hospitalization have severe illness, according to research published in the Dec. 31 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
FDA May Allow Pfizer Boosters for 12- to 15-Year-Olds by Monday
THURSDAY, Dec. 30, 2021 (HealthDay News) — Younger adolescents may soon be eligible for COVID-19 booster vaccines, possibly by early next week.
Seniors Report Medical Care Missed During the Pandemic
THURSDAY, Dec. 30, 2021 (HealthDay News) — Medicare beneficiaries experienced limited care access during the COVID-19 pandemic, although there was a decrease in forgone medical care over time, according to a study published online Dec. 30 in JAMA Health Forum.
Most COVID-19-Related EUAs Not Supported by High-Quality Evidence
THURSDAY, Dec. 30, 2021 (HealthDay News) — During the first year of the COVID-19 pandemic, emergency use authorizations from the U.S. Food and Drug Administration of COVID-19-related medical products were for diagnostic products and were supported by comparisons to previously authorized assays, according to a research letter published online Dec. 20 in JAMA Internal Medicine.
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization
THURSDAY, Dec. 30, 2021 (HealthDay News) — For patients at high risk for venous thromboembolism discharged after COVID-19 hospitalization, thromboprophylaxis with rivaroxaban is associated with improved clinical outcomes, according to a study published online Dec. 15 in The Lancet.
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
Most U.S. Adults Unsure Which Vaccines CDC Recommends During Pregnancy .jpg)
Pregnancy Complications Rare for Women Receiving CAR T-Cell Therapy 
Higher Parental Vitamin B12 Tied to Lower Prevalence of Birth Defects 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
